BDBM411333 US10385031, Compound 039::US10774056, Compound 039::US11542242, Compound 039

SMILES Nc1ccc(cc1NC(=O)c1ncc(s1)N1CCNCC1)-c1cccs1

InChI Key InChIKey=SLBMZHYVOUGKNR-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 411333   

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/13/2020
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 3.60E+3nMAssay Description:For hERG inhibition assays, the cells used were HEK293 cells stably transfected with hERG (cell line obtained from Cytocentrics Inc. 3463 Magic Drive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 255nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2021
Entry Details
Go to US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 3.60E+3nMAssay Description:For hERG inhibition assays, the cells used were HEK293 cells stably transfected with hERG (cell line obtained from Cytocentrics Inc. 3463 Magic Drive...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetHistone deacetylase 1(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetHistone deacetylase 2(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 10nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent

TargetHistone deacetylase 3(Human)
Regenacy Pharmaceuticals

US Patent
LigandPNGBDBM411333(US10385031, Compound 039 | US10774056, Compound 03...)
Affinity DataIC50: 255nMAssay Description:Compounds for testing were diluted in DMSO to 50 fold the final concentration and a ten-point three-fold dilution series was made. The compounds were...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
Go to US Patent